Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCMA targeted prime CAR-T cells · 1 trial · 3 indications
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
The response rate of BCMA targeted prime CAR-T treatment will be recorded and assessed according to the IMWG
| Arm | Type | Description |
|---|---|---|
| BCMA targeted prime CAR-T cells treat | EXPERIMENTAL | Patients will be be treated with BCMA targeted prime CAR-T cells |
| Name | Type | Description |
|---|---|---|
| BCMA targeted prime CAR-T cells | BIOLOGICAL | BCMA targeted prime CAR-T cell therapy |
Inclusion Criteria: 1. Signed written informed consent; 2. Diagnose as relapsed /refractory multiple myeloma or other plasma cell disease, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory...
Top 20 of 25 competitors
BCMA targeted prime CAR-T cells is an investigational cell therapy being studied for the treatment of multiple myeloma, including relapsed or refractory multiple myeloma and plasma cell disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BCMA targeted prime CAR-T cells targets B-cell maturation antigen (BCMA), a protein expressed on myeloma cells. The therapy is designed to recognize and attack BCMA-positive cells as part of its mechanism of action in treating multiple myeloma.
BCMA targeted prime CAR-T cells is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DTIL. The company is conducting a Phase 1 clinical trial for this investigational therapy.
BCMA targeted prime CAR-T cells is in Phase 1 clinical development. It is an investigational therapy that has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is actively recruiting participants to evaluate the treatment.
BCMA targeted prime CAR-T cells is being evaluated in a Phase 1 clinical trial registered as NCT04776330. This open-label, uncontrolled study is recruiting approximately 80 participants in China with relapsed or refractory multiple myeloma and plasma cell disease.
BCMA targeted prime CAR-T cells is a cell therapy, not a monoclonal antibody. While the drug asset is categorized under the modality of monoclonal antibody in some databases, its mechanism involves engineered T cells targeting BCMA, distinguishing it from traditional antibody-based therapies.